2214 Federal Register / Vol. 83, No. 10 / Tuesday, January 16, 2018 / Notices 

argument that a different standard of 

proof should apply. 

B. In any enforcement proceeding in 

which the Court finds that TransDigm 

has violated this Final Judgment, the 

United States may apply to the Court for 

a one-time extension of this Final 

Judgment, together with such other 

relief as may be appropriate. TransDigm 

agrees to reimburse the United States for 

any attorneys’ fees, experts’ fees, and 

costs incurred in connection with any 

effort to enforce this Final Judgment. 

XVI. Expiration of Final Judgment 

Unless this Court grants an extension, 

this Final Judgment shall expire ten (10) 

years from the date of its entry, except 

that after five (5) years from the date of 

its entry, this Final Judgment may be 

terminated upon notice by the United 

States to the Court and TransDigm that 

the divestiture has been completed and 

that the continuation of the Final 

Judgment no longer is necessary or in 

the public interest. 

XVII. Public Interest Determination 

Entry of this Final Judgment is in the 

public interest. The parties have 

complied with the requirements of the 

Antitrust Procedures and Penalties Act, 

15 U.S.C. 16, including making copies 

available to the public of this Final 

Judgment, the Competitive Impact 

Statement, and any comments thereon 

and the United States’ responses to 

comments. Based upon the record 

before the Court, which includes the 

Competitive Impact Statement and any 

comments and response to comments 

filed with the Court, entry of this Final 

Judgment is in the public interest. 

Date: llllllllllllllll

Court approval subject to procedures 

of Antitrust Procedures and Penalties 

Act, 15 U.S.C. 16. 

lllllllllllllllllll

United States District Judge. 

APPENDIX A: Real Property 

(Owned and Leased) 

SCHROTH U.S. Leased Real Property 

Facility name Address Type of facility 

Pompano Beach ................................................. 1371 SW 8th Street, Pompano Beach, FL ...... Manufacturing Plant, Office, and Warehouse. 

SCHROTH Germany Leased Real 

Property 

Facility name Address Type of facility 

Headquarters ‘‘Im Ohl’’ ....................................... Im Ohl 14, 59757, Arnsberg, Germany ........... Manufacturing Plant and Office (Headquarters). 

Parking Area ‘‘Im Ohl’’ ........................................ Im Ohl 14, 59757, Arnsberg, Germany ........... Parking Area. 

SCHROTH Germany Owned Real 

Property 

Facility name Address Type of facility 

Warehouse ‘‘Im Ohl’’ .......................................... Im Ohl 14, 59757, Arnsberg, Germany; Land 

Register of Neheim-Husten of the local 

court of Arnsberg; Page 13024; Plot 5, Parcel 390.

Warehouse. 

Warehouse ‘‘Im Ohl’’ .......................................... Im Ohl 14, 59757, Arnsberg, Germany; Land 

Register of Neheim-Husten of the local 

court of Arnsberg; Page 9777; Plot 5, Parcel 88.

Warehouse. 

[FR Doc. 2018–00544 Filed 1–12–18; 8:45 am] 

BILLING CODE 4410–11–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Janssen Pharmaceuticals, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before February 15, 2018. Such 

persons may also file a written request 

for a hearing on the application 

pursuant on or before February 15, 

2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 10 / Tuesday, January 16, 2018 / Notices 2215 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on 

September 19, 2017, Janssen 

Pharmaceuticals Inc., 1400 Olympic 

Drive, BLDGS 1–5 & 7–14, Athens, 

Georgia 30601 applied to be registered 

as an importer of the following basic 

classes of controlled substances: 

Controlled substance Drug 

code Schedule 

Tapentadol .................... 9780 II 

Thebaine ....................... 9333 II 

Concentrated Poppy 

Straw.

9670 II 

The company plans to import an 

intermediate form of tapentadol (9780) 

to bulk manufacture tapentadol for 

distribution to its customers. The 

company plans to import thebaine 

derivatives (9333) as reference 

standards. The company plans to import 

concentrated poppy straw to 

manufacture other controlled 

substances. No other activity for these 

drug codes is authorized for this 

registration. Approval of permit 

applications will occur only when the 

registrant’s business activity is 

consistent with what is authorized 

under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of FDA approved or nonapproved finished dosage forms for 

commercial sale. 

Dated: January 4, 2018. 

Susan A. Gibson, 

Deputy Assistant Administrator. 

[FR Doc. 2018–00508 Filed 1–12–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Catalent Pharma 

Solutions, LLC 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before February 15, 2018. Such 

persons may also file a written request 

for a hearing on the application 

February 15, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on October 

13, 2017, Catalent Pharma Solutions, 

LLC, 1100 Enterprise Drive, Winchester, 

KY 40391 applied to be registered as an 

importer for Gamma Hydroxybutyric 

Acid (2010) the basic class of controlled 

substances. 

The company plans to import the 

listed controlled substance in finished 

dosage form for analytical purposes 

only. No other activity for these drug 

codes is authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under to 21 U.S.C. 

952(a)(2). Authorization will not extend 

to the import of FDA approved or nonapproved finished dosage forms for 

commercial sale. 

Dated: January 4, 2018. 

Susan A. Gibson, 

Deputy Assistant Administrator. 

[FR Doc. 2018–00507 Filed 1–12–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Johnson 

Matthey Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before March 19, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on 

November 10, 2017, Johnson Matthey 

Inc., Pharmaceuticals Materials, 900 

River Road, Conshohocken, 

Pennsylvania 19428 applied to be 

registered as a bulk manufacturer of the 

following basic classes of controlled 

substances: 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

Amphetamine ............... 1100 II 

Methylphenidate ........... 1724 II 

Codeine ........................ 9050 II 

Oxycodone ................... 9143 II 

Diphenoxylate ............... 9170 II 

Hydrocodone ................ 9193 II 

Meperidine .................... 9230 II 

Methadone .................... 9250 II 

Methadone intermediate 9254 II 

Morphine ....................... 9300 II 

Thebaine ....................... 9333 II 

Opium tincture .............. 9630 II 


daltland on DSKBBV9HB2PROD with NOTICES